Home  /  Resource Library  /  A Phase 2 Study Of Rituximab, Bendamustine, Bortezomib And Dexamethasone For First-Line Treatment Of Older Patients With Mantle Cell Lymphoma

A Phase 2 Study Of Rituximab, Bendamustine, Bortezomib And Dexamethasone For First-Line Treatment Of Older Patients With Mantle Cell Lymphoma

Results of a phase II trial examining the combination of Rituximab, Bendamustine, Bortezomib And Dexamethasone for front line treatment of elderly patients with MCL.